Abingdon Life Sciences, Inc. Enters Into Strategic Alliance With Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support

Published: Aug 04, 2008

CARLSBAD, Calif., Aug. 4 /PRNewswire/ -- Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc. to provide clinical and regulatory support for Stason's drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason's pipeline of potential drug candidates and devices in the areas of cancer and inflammation.

"We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing," said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added, "Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets."

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.

About Stason Pharmaceuticals, Inc.:

Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.

CONTACT: Aidan Nuttall, Ph.D., of Abingdon Life Sciences, Inc.,
+1-760-268-1078, anuttall@abingdoncorp.com, or Diana Wood of Stason
Pharmaceuticals, Inc., +1-760-929-0346, diana.wood@stasonpharma.com

Back to news